Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Group 1: Financial Performance - Fiserv reported Clover gross payment volume (GPV) growth of only 8% for Q1 2025, a significant decline from the 14% to 17% growth rates observed in 2024 [3]. - The company attributed the slowdown in growth to reduced transaction volumes from merchants transitioning from the older Payeezy platform to the newer Clover platform [3]. - On July 23, 2025, Fiserv lowered the top end of its full-year organic growth guidance and confirmed that quarterly organic revenue in the Merchant segment decelerated to 9% year-over-year from 11% in the previous quarter [5]. Group 2: Stock Price Impact - Following the Q1 2025 report, Fiserv's stock price fell by $40.20 per share, or 18.52%, closing at $176.90 on April 24, 2025 [4]. - On May 15, 2025, after disclosing continued GPV growth deceleration, the stock price dropped by $30.73 per share, or 16.19%, closing at $159.13 [4]. - After the July 23 announcement regarding lowered growth guidance, Fiserv's stock price fell by $22.90 per share, or 13.85%, closing at $143.00 [5].

Core Viewpoint - Dow Inc. is under investigation for potential securities fraud and unlawful business practices following a significant decline in its financial performance and stock price [1][2]. Financial Performance - For Q2 2025, Dow reported net sales of $10.1 billion, a decrease of 7% year-over-year, with declines observed across all operating segments [2]. - Sequentially, net sales fell by 3%, with seasonally higher demand in Performance Materials & Coatings being offset by declines in other segments [2]. - Following the financial results announcement, Dow's stock price dropped by $5.30 per share, or 17.45%, closing at $25.07 per share on July 24, 2025 [2]. Corporate Actions - Dow's CEO announced adjustments to the company's dividend to maintain a balanced capital allocation framework [2].

Core Insights - Simulations Plus is under investigation for potential securities fraud and unlawful business practices [1] - The company reported third fiscal quarter sales of $20.4 million, missing the consensus estimate of $20.9 million, and incurred a net loss of $67.3 million, including a non-cash impairment charge of $77.2 million [2] - Following the financial report, Simulations Plus's stock price dropped by $4.50, or 25.76%, closing at $12.97 per share [3] - The company revised its fiscal 2025 adjusted earnings guidance down to $0.93 to $1.06 from a previous range of $1.07 to $1.20 [2] - A restructuring initiative was initiated in June, involving workforce reductions and cost-cutting measures to enhance operational efficiency [2]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Fiserv, Inc. for alleged misleading statements and failures to disclose critical information regarding its Clover platform and Payeezy merchants during the Class Period from July 24, 2024, to July 23, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Fiserv made false statements about its Clover platform's growth and business prospects, which were misleading to investors [5]. - Allegations include that Fiserv forced Payeezy merchants to migrate to Clover, which temporarily inflated Clover's revenue growth and gross payment volume (GPV) [5]. - The lawsuit states that many former Payeezy merchants switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's GPV growth [5]. Group 2: Investor Participation - Investors who purchased Fiserv common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can submit a form or contact the law firm for more information [3][6]. - A lead plaintiff is needed to represent other class members, and interested parties must move the Court by September 22, 2025 [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - Class action lawsuits have been filed against several publicly-traded companies, alleging misleading statements and failure to disclose critical information that may have impacted shareholders' investments [1]. Group 1: Hims & Hers Health, Inc. (NYSE: HIMS) - The class period for Hims & Hers Health, Inc. is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include deceptive promotion and selling of illegitimate versions of Wegovy, risking patient safety, and potential termination of collaboration with Novo Nordisk [2]. Group 2: iRobot Corporation (NASDAQ: IRBT) - The class period for iRobot Corporation is from January 29, 2024, to March 11, 2025, with a lead plaintiff deadline of September 5, 2025 [3]. - Allegations state that iRobot overstated the effectiveness of its Restructuring Plan post-Amazon Acquisition, raising doubts about its ability to operate profitably as a standalone company [3]. Group 3: Centene Corporation (NYSE: CNC) - The class period for Centene Corporation is from December 12, 2024, to June 30, 2025, with a lead plaintiff deadline of September 8, 2025 [4]. - Allegations include lower-than-expected enrollment and increased market morbidity affecting over two-thirds of Centene's marketplace share, leading to misleading statements about the company's prospects [4]. Group 4: Biohaven Ltd. (NYSE: BHVN) - The class period for Biohaven Ltd. is from March 24, 2023, to May 14, 2025, with a lead plaintiff deadline of September 12, 2025 [5]. - Allegations involve overstated regulatory prospects for treatments and potential negative impacts on Biohaven's business and financial condition once the truth is revealed [5].

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims against RxSight, Inc. for misleading statements regarding its business and financial performance during the specified Class Period [1][4]. Company Background - RxSight, Inc. is a commercial-stage medical technology company that specializes in the research, development, manufacturing, and marketing of light-adjustable intraocular lenses (LAL) used in cataract surgery [3]. Securities Fraud Claims - The class action complaint alleges that RxSight made materially false and misleading statements, failing to disclose declines in product sales and utilization, and overstating demand for its intraocular lens products [4]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [4]. Financial Performance - On July 9, 2025, RxSight reported significant declines in sales of its Light Delivery Device (LDD), usage of its light-adjustable intraocular lenses (LALs), and total revenue, leading to a reduction in its Full Year 2025 guidance by approximately $42.5 million [5]. - Following this disclosure, RxSight's stock price fell by $4.84 per share, or 37.8%, closing at $7.95 per share on July 9, 2025 [5].

Core Viewpoint - A securities class action lawsuit has been filed against Apple Inc. for allegedly making false and misleading statements regarding the integration of advanced AI-based Siri features into its devices, which may impact iPhone 16 sales and overall business prospects [2][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of investors who purchased Apple securities between June 10, 2024, and June 9, 2025 [1]. - The lead plaintiff deadline for the lawsuit is August 19, 2025 [1][3]. Group 2: Allegations Against Apple - The complaint alleges that Apple misstated the time required to integrate advanced AI-based Siri features, making it unlikely these features would be available for the iPhone 16 [2]. - The absence of these advanced features is claimed to negatively affect iPhone 16 sales, leading to an overstatement of Apple's business and financial prospects [2]. Group 3: Lead Plaintiff Process - Investors may seek to be appointed as a lead plaintiff representative of the class by the deadline or may choose to remain absent [3]. - The lead plaintiff will act on behalf of all class members and select counsel to represent the class [3]. Group 4: Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

Core Viewpoint - Johnson Fistel, PLLP is investigating RXO, Inc. for potential violations of federal securities laws related to misrepresentation or failure to disclose material information to investors [1] Group 1: Investigation Details - The investigation focuses on whether RXO, Inc. or its officers and directors misrepresented or failed to disclose important information to investors [1] - Individuals who purchased RXO securities and experienced losses are encouraged to join the investigation [2] Group 2: Whistleblower Information - Individuals with nonpublic information about RXO are advised to consider assisting the investigation or utilizing the SEC Whistleblower program, which may offer rewards up to 30% of successful recoveries [3] Group 3: About Johnson Fistel, PLLP - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights, with offices across multiple states [4] - The firm has been ranked in the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services in 2024, recovering approximately $90,725,000 for clients [5]

Core Viewpoint - DJS Law Group is investigating claims against RxSight, Inc. for potential violations of securities laws related to misleading statements and undisclosed information impacting investors [1][2]. Investigation Details - The investigation centers on RxSight's financial performance, particularly the decline in sales of Light Delivery Devices (LDD) and total revenue [2]. - RxSight reported a significant drop in key metrics and lowered its full-year financial guidance, attributing the changes to "adoption challenges" leading to an "LDD stall" [2]. - Following the financial report, RxSight's shares plummeted by nearly 38% on the announcement day [2].

Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. for alleged violations of securities laws, specifically related to misleading statements about the company's clinical trial results [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Replimune's securities between November 22, 2024, and July 21, 2025 [2]. - The Schall Law Firm is representing the investors and encourages those who suffered losses to participate in the lawsuit [5]. Group 2: Allegations Against the Company - The complaint alleges that Replimune made false and misleading statements regarding the IGNYTE trial for RP1 (vusolimogene oderparepvec) [4]. - It is claimed that the company overstated the prospects of the trial and was aware of material issues that could lead to the FDA deeming the trial inadequate [4]. - As a result of these misleading statements, investors experienced financial damages when the truth about the company's situation was revealed [4].